On April 10, 2025, Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a new bevacizumab biosimilar referencing Genentech ...

Patients will receive relacorilant in combination with nab-paclitaxel and bevacizumab. “In our pivotal Phase 3 ROSELLA trial, treatment with relacorilant and nab-paclitaxel improved patients ...

The Company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd ...

The most common (≥25%) adverse reactions, including laboratory abnormalities, in patients receiving tisotumab vedotin were peripheral ... chemotherapy doublet +/- bevacizumab and an anti-PD ...

JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin ® (bevacizumab). JOBEVNE is a vascular ...